1. Merck announces phase 3 KEYNOTE-522 trial met its overall survival (OS) endpoint in patients with high-risk early-stage triple negative breast cancer (TNBC). News release. May 28, 2024. Accessed May 28, 2024. 2. Schmid P, Cortés J, Dent RA, et al. LBA18 Pembrolizumab or placebo...
1.https://endpts.com/weeks-after-keytruda-crl-in-high-risk-tnbc-merck-claims-a-win-after-data-mature-how-soon-will-it-return-to-fda/ 2.https://www.merck.com/news/merck-announces-phase-3-keynote-522-trial-met-dual-primary-endpoint-of-event-free-survival-efs-in-patients-with-high-risk...
参考资料: [1]https://www.merck.com/news/merck-announces-phase-3-keynote-522-trial-met-dual-primary-endpoint-of-event-free-survival-efs-in-patients-with-high-risk-early-stage-triple-negative-breast-cancer-tnbc/ [2]https://news.medlive.cn/all/info-progress/show-166678_53.html 医药 免疫疗...
The KEYNOTE-522 trial is the first randomised phase 3 trial of an immune checkpoint inhibitor in early triple negative breast cancer. We've seen data in metastatic triple negative breast cancer with immune checkpoint inhibitors showing a clear benefit in survival. When it comes to early triple ...
RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the Phase 3 KEYNOTE-522 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, met its overall s...
4.Schmid P, Rugo HS, Adams S, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomis...
(LBO1-02) Pathologic complete response (pCR) of neoadjuvant therapy with or without atezolizumab in HER2-positive, early high-risk and locally advanced breast cancer: APTneo Michelangelo randomized trial 中文标题: (LBO1-02...
As reported inThe New England Journal of MedicinebyPeter Schmid, MD, PhD, and colleagues, a preplanned interim analysis of the phase III KEYNOTE-522 trial has shown improved event-free survival with the addition of pembrolizumab to neoadjuvant chemotherapy, foll...
analysis of the HERceptin Adjuvant (HERA) trial. Lancet. 2017;389(10075):1195-1205.[5].Li J, Yu K, Pang D, et al. Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial...
KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive results from the pivotal neoadjuvant/adjuvant Phase 3 KEYNOTE-522 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy as ...